Home » 2019 » May
Causes and Symptoms of Nose Bleeding

Causes and Symptoms of Nose Bleeding

Nose Bleeding is the bleeding from the nose that can range anything between a minor tickle to sudden flow of blood from the nose. Nose bleeding is not a major worry even though they look scary when blood comes out of nose. Nosebleeds can be treated with some effective home remedies that will be discussed […]

Over consumption of licorice tea may have harmful side effects

Excessive consumption of the popular herbal beverage, licorice tea may have harmful side effects like high blood pressure and reduced potassium levels. As per the case study published in Canadian Medical Association Journal (CMAJ), consumption of licorice tea made from licorice roots resulted in high blood pressure in an 84-year old man. Jean-Pierre Falet from […]

Continue reading …
Vaginal Infection : Causes, Symptoms and Home Remedies

Vaginal discharge, is a vital function of the female reproductive system, is the fluid secreted by the glands in the vagina that helps to remove dead cells, bacteria and other impurities by the cervix. Vaginal discharge keeps the vagina clean and protects from infections. But when the vaginal discharge becomes yellowish white in colour with […]

Continue reading …
Greiner Bio-One launches new MiniCollect K2EDTA Capillary Collection Tube

Austrian medical technology manufacturer Greiner Bio-One has launched the newly redesigned MiniCollect K2EDTA Capillary Collection Tube, designed for collecting, transporting and evaluating capillary blood samples. The newly redesigned tube has an integrated scoop which allows easy collection of droplets of blood after skin puncture, thus cutting down on the number of accessories needed. When the […]

Continue reading …
Cell therapy company Talaris Therapeutics raises $100m in Series A round

Talaris Therapeutics (formerly Regenerex) has raised $100 million in a Series A financing round to advance its allogeneic cell therapy FCR001 into phase 3 development in various immune-related indications. Blackstone Life Sciences led the financing round of the US biotech company with the other participants being Qiming Venture Partners USA and Longitude Capital. Talaris Therapeutics […]

Continue reading …
Know how to control oily skin : Dos and Don’ts

Check below some dos and don’ts that should be followed to tackle with the oily skin. Select right face wash If you are having oily skin, select a face wash that suits best for your skin. The cream should be transparent without any creamy formula. Select the face wash that contains benzoyl peroxide, tea tree […]

Continue reading …
Common signs of heart attack in women not to ignore

All knew that chest pain is the common signs of heart attack. In the real life the common symptoms of heart attack include other signs of cardiovascular problems which are required to be known by everyone in addition to the pain in the chest. According to the studies, women mostly feel chest pain due to […]

Continue reading …
Teva launches generic version of Delzicol delayed-release capsules in US

Israeli pharma company Teva Pharmaceuticals has launched a generic version of Delzicol (mesalamine) 400mg delayed-release capsules in the US. Mesalamine Delayed-Release capsules are an aminosalicylate, approved for the treatment of mild to moderate ulcerative colitis in patients aged five years and above, and also for maintenance of remission of ulcerative colitis in adult patients. Brendan […]

Continue reading …
Pharma giants bag Lynparza EMA approval for metastatic breast cancer

Lynparza EMA approval : Pharma giants AstraZeneca and MSD have secured an expansion of the European Medical Agency’s (EMA) approval for their poly ADP-ribose polymerase (PARP) inhibitor Lynparza (olaparib) to be used for the treatment of a type of advanced breast cancer. The expanded Lynparza EMA approval allows the PARP inhibitor to be used as […]

Continue reading …
Vaxiion begins VAX014 phase 1 trial in non-muscle invasive bladder cancer

Vaxiion Therapeutics, a clinical stage biotech company based in California, has initiated a phase 1 clinical trial of its recombinant bacterial minicell-based oncolytic immunotherapy VAX014 for the treatment of non-muscle invasive bladder cancer (NMIBC). The development comes following the conclusion of a 30-day review of the investigational new drug application (IND) of VAX014 by the […]

Continue reading …
Page 1 of 212